Cannabis is composed of more than 400 chemical components. A number of these components are found to provide therapeutic relief in alleviating chronic pain, seizure, depression and muscle spasms resulting from multiple sclerosis 1 , but the primary psychoactive ingredient in cannabis, Δ 9 -tetrahydrocannabinol (1, THC), produces some unwanted effects on human health, such as motor impairment and psychosis. Although most THC-induced central effects are mediated through the activation of a cannabinoid type 1 (CB1) receptor, evidence has emerged to suggest that some of the THC-induced cellular and behavioral effects are independent of CB1 receptors [2] [3] [4] . For instance, intrathecal injection of a selective CB1 antagonist cannot completely inhibit the analgesic effects induced by THC and deoxy-HU 210 (2), a synthetic cannabinoid structurally similar to THC, in spinal tail-flick reflex test (TFR) in mice . There are indications from very recent studies that endogenous CB1 receptors may play a pronociceptive role instead of an antinociceptive role in spinal dorsal horn, an area critical for pain sensory formation 6, 7 . A number of nonpsychoactive cannabinoids structurally similar to THC are found to exert neuroprotection, antiemetic and antinociceptive effects 8, 9 . Although the therapeutic potential of nonpsychotropic cannabinoids has been the topic of interest over the last several decades 9 , relatively less is known about the molecular sites and mechanisms that mediate nonpsychoactive cannabinoid-induced actions.
1 article puBLIsHed OnLIne: 3 aprIL 2011 | dOI: 10.1038/nCHeMBIO.552 C annabis attracts broad scientific interest because it produces both beneficial and harmful effects on human health 1 . Cannabis is composed of more than 400 chemical components. A number of these components are found to provide therapeutic relief in alleviating chronic pain, seizure, depression and muscle spasms resulting from multiple sclerosis 1 , but the primary psychoactive ingredient in cannabis, Δ
9
-tetrahydrocannabinol (1, THC), produces some unwanted effects on human health, such as motor impairment and psychosis. Although most THC-induced central effects are mediated through the activation of a cannabinoid type 1 (CB1) receptor, evidence has emerged to suggest that some of the THC-induced cellular and behavioral effects are independent of CB1 receptors [2] [3] [4] . For instance, intrathecal injection of a selective CB1 antagonist cannot completely inhibit the analgesic effects induced by THC and deoxy-HU 210 (2), a synthetic cannabinoid structurally similar to THC, in spinal tail-flick reflex test (TFR) in mice 5 . THC-induced analgesia in the TFR remains intact in mice with depleted CB1 receptors (CB1 −/− ) 2 . There are indications from very recent studies that endogenous CB1 receptors may play a pronociceptive role instead of an antinociceptive role in spinal dorsal horn, an area critical for pain sensory formation 6, 7 . A number of nonpsychoactive cannabinoids structurally similar to THC are found to exert neuroprotection, antiemetic and antinociceptive effects 8, 9 . Although the therapeutic potential of nonpsychotropic cannabinoids has been the topic of interest over the last several decades 9 , relatively less is known about the molecular sites and mechanisms that mediate nonpsychoactive cannabinoid-induced actions.
Emerging evidence has suggested that inhibitory glycine receptors (GlyRs) are an important target for cannabis in the central and peripheral nervous systems 4, 10 . THC and other cannabinoids can increase the activity of native and recombinant GlyRs through a CB1-and CB2-independent mechanism [10] [11] [12] . THC and GlyRs share similar roles in regulation of some behaviors, such as neuromotor activity, pain sensation, muscle relaxation and anxiety 1, 13 .
Humans and rodents carrying single amino acid mutations on the α1 GlyRs at postsynaptic sites have severe deficiency in neuromotor activity 14, 15 . The α3 GlyRs are abundantly expressed in the adult spinal cord dorsal horn where these receptors critically regulate inflammatory pain sensation 16 . Nevertheless, the idea that the GlyRs are an important target for cannabinoids has been largely ignored because our knowledge is limited regarding the mechanisms and behavioral implication of cannabinoid potentiation of GlyRs. Here we identify a new mechanism by which THC potentiates GlyRs. We also provide evidence to suggest that the site and the action of mechanism of cannabinoid potentiation of GlyRs critically contribute to the cannabisinduced analgesic effect. These findings could help to identify a new strategy for developing analgesic agents.
RESULTS

THC potentiation of native and recombinant GlyRs
THC at relatively low concentrations enhanced I Gly in cultured spinal neurons (Fig. 1a) . The magnitudes of the potentiating effect on I Gly induced by 30 nM, 100 nM and 300 nM THC were 44 ± 13%, 82 ± 4% and 136 ± 11%. THC-induced potentiating effect on I Gly developed gradually with continuous application of THC for 5 min in both cultured spinal neurons and HEK 293 cells expressing the α1 and α1β1 GlyR subunits (Fig. 1b) . The peak amplitude of THC potentiation was nearly ten-fold higher than the initial value of THC potentiation. It is well accepted that the native GlyRs in adult brains are formed by the α-and β-subunits 17 . Consistent with this, the sensitivities of the native and heteromeric α1β1 GlyRs to THC were nearly identical but were significantly less than that of the homomeric α1 receptors. In addition to activating CB1 and CB2 receptors, THC is found to directly activate vanilloid receptors in rat trigeminal neurons 18 . In this regard, we examined whether CB1, CB2 and vanilloid receptors are involved in THC potentiation of GlyRs. did not significantly alter the THC-induced potentiating effect on I Gly in both spinal neurons and HEK 293 cells expressing the α1 GlyRs (Fig. 1c) . THC is unlikely to alter GlyR trafficking, as there was no apparent difference in the levels of total and surface α1 GlyR proteins in the absence and presence of THC detected by immunoblot ( Fig. 1d and Supplementary Results, Supplementary Fig. 6 ).
Ser296 is a distinct site essential for THC potentiation
To localize molecular domains of GlyRs that mediate THC potentiation, we first examined whether THC can differentially affect three distinct α-subunits of GlyRs. Although the α1 and α3 GlyR subunits appeared to be equally sensitive to the THC-induced potentiating effect, the α2 GlyR subunits were significantly less sensitive to THC when expressed in HEK 293 cells (Fig. 2a-c) . The magnitudes of average percent potentiation induced by 1 μM THC were 1,156 ± 472% and 1,127 ± 142% in cells expressing the α1 and α3 subunits. In contrast, the magnitude of THC potentiation of the α2 subunit was 232 ± 35% (Fig. 2b) . The maximal efficacy of THC in potentiating I Gly was also significantly less in the cells expressing the α2 subunits than the cells expressing the α1 and α3 subunits (Fig. 2c) . A recent study has shown that CP55940 (6), a synthetic CB1 agonist structurally similar to THC, was exclusively concentrated in the membrane lipid matrix where CP55940 could access to the binding pockets in the receptor transmembrane domains 19 . In view of this finding, we focused on the transmembrane domains of GlyRs in looking for potential molecular determinants of THC potentiation. Alignment of the amino acid sequence of all four transmembrane domains across three α subunits revealed a serine residue at 296 in the transmembrane domain 3 (TM3) that is identical in the α1 and α3 subunits but not in the α2 subunit (Fig. 2d) . Aligned with Ser296 in the α1 subunit is Ala303 in the α2 subunit. Throughout the entire four transmembrane domains, Ala303 is the only residue that differs from both of the equivalent residues (Ser296 and Ser307) in the α1 and α3 subunits. Substitution of Ser296 in the α1 subunit with an alanine significantly reduced the maximal magnitude of THC potentiation by nearly 80% and resulted in a concentration response curve of THC potentiation identical to that of the α2 subunits (Fig. 2e) . A similar scenario also occurred in the α3 subunit where the substitution of Ser307 with an alanine significantly reduced the sensitivity of the α3 subunit to THC (Fig. 2f) . Conversely, substitution of the corresponding residue, Ala303, of the α2 subunit with a serine converted the α2 subunit from a receptor with a low THC sensitivity to a high THC sensitivity (Supplementary Fig. 1a) . It is worth mentioning that, similar to our observation in neurons, THC at low concentrations (30-300 nM) significantly enhanced I Gly in HEK 293 cells expressing the α1 and α3 subunits. The S296A and S307A mutations significantly reduced the magnitude of the potentiation induced by low concentrations of THC. For instance, the extents of the potentiating effect induced by 100 nM THC were 97 ± 7% and 23 ± 4% in cells expressing the wild-type and S307A mutant α3 subunits (P < 0.01, unpaired t-test, n = 6). The point mutations of S296A in the α1 subunit, A303S in the α2 subunit and S307A in the α3 subunit did not significantly affect the half-maximal effective concentration (EC 50 ) values of the GlyRs (Supplementary Fig. 1b) . The S296A mutation of the α1 subunit did not significantly affect propofol (7)-, trichloroethanol (8)-, etomidate (9)-and ethanol (10)-induced potentiation, suggesting that the Ser296 is a distinct site for THC-induced action ( Supplementary Fig. 1c,d ).
NMR: THC induces a chemical shift of Ser296
Next we carried out NMR chemical shift measurements to determine whether or not THC directly interacts with the transmembrane domains of GlyR. The proteins of the full-length transmembrane domains of the human α1 GlyR were overexpressed and purified using Rosetta (DE3) pLysS-competent E. coli cells as described in Methods and Supplementary Methods. Molecular modeling of the four transmembrane domains of the α1 subunit reveals the specific location of Ser296 in green (Fig. 3a) . Titration of THC to the transmembrane domains of the human α1 GlyR subunit (GlyR-TM) reconstituted in lyso-1-palmitoylphosphphotidylglycerol (LPPG) micelles showed that most of the resonances of the transmembrane domains in the 2D 15 N heteronuclear single quantum coherence (HSQC) spectra remained unchanged after the addition of THC, suggesting that the interaction between THC and GlyR-TM does not alter the overall structure of GlyR-TM. However, the resonance of Ser296 was highly sensitive to THC (Fig. 3b) . We next tested the effect of ethanol on the resonance of Ser296 because ethanol was used as a solvent to dissolve THC. Ethanol alone caused a Ser296 resonance shift in the up field direction (Fig. 3c) . In contrast, the Ser296 resonance shifted steeply in the downfield direction, showing a high sensitivity to THC (Fig. 3d, green and pink open circles). The titration curves showed two distinct concentration dependences at low and high ligand-to-protein ratios (Fig. 3e) . At low ligand-toprotein ratios (0-17 μM of THC titrated to 450 μM of protein), the Ser296 resonance shifted steeply in the downfield direction, showing a hypersensitivity to THC (green and pink solid circles). This is a strong indication that THC interacts selectively with Ser296. At higher ligand-to-protein ratios, a typical saturation curve was observed. The discontinuity in the THC titration curve at the high concentration range is likely due to the interfering effect induced by ethanol. The amount of ethanol increased dramatically (up to 86 mM) when titrated in the range with high ligand-to-protein ratio. It is possible that ethanol, especially at high concentrations, may inhibit the interaction between THC and Ser296 under the NMR experimental conditions. There were a few peaks that were slightly modified in the presence of high concentrations of THC (>90 μM). These peaks arose from the residues in an artificial flexible linker engineered to connect TM3 with TM4 or in a C-terminal His tag.
Evidence for a hydrogen bond-like interaction
To further explore the molecular insight into the role of Ser296 in THC-induced potentiation of GlyRs, we used mutagenesis to analyze the interrelationship between THC potentiation and the biophysical properties of the amino acid residues at 296 and 307 of the α1 and α3 subunits. The sensitivity of the mutant receptors to the THC-induced potentiating effect on I Gly varied substantially (Fig. 4a) . There was a strong correlation between the polarity of the amino acid residue at 296 α1 or 307 α3 and THC potentiation of the α1 and α3 subunits (r 2 = 0.608, r 2 = 0.768, Fig. 4b,c) . In contrast, the magnitude of THC potentiation was not significantly correlated with the volume of the residue at 296, the glycine EC 50 value and mean current density of the wild-type and mutant receptors (Fig. 4d-f) . These observations suggest that THC is likely to interact with Ser296 of GlyRs via a hydrogen bond interaction. To further test this hypothesis, we chemically modified THC by removing the hydroxyl, oxygen or both groups from the THC (see detailed procedure of chemical synthesis in Supplementary Methods). The resulting chemicals are named as follows: 5-desoxy-THC (11), 1-desoxy-THC (12) and didesoxy-THC (13, DiDe-THC) (Supplementary Fig. 2 ). Chemical modification of THC significantly reduced the binding affinity of 5-desoxy-THC and 1-desoxy-THC to CB1 but not to CB2 receptors (Fig. 5a,b) . In contrast, di-desoxy-THC with both hydroxyl and oxygen groups removed completely lost the binding affinity for both CB1 and CB2 receptors. Di-desoxy-THC and 5-desoxy-THC did not stimulate [ (Fig. 5c) . Although 5-desoxy-THC and 1-desoxy-THC potentiated I Gly in a manner similar to THC, di-desoxy-THC was nearly ineffective in potentiating I Gly (Fig. 5d) . However, di-desoxy-THC significantly inhibited the THC-induced potentiating effect on I Gly (Fig. 5e) . Di-desoxy-THC did not significantly affect the potentiating effect on I Gly induced by 100 μM propofol (Fig. 5f) , suggesting that di-desoxy-THC selectively antagonizes the THC-induced potentiating effect.
The a3 GlyRs: essential for cannabis-induced analgesia
The above observations suggest that using both 5-desoxy-THC and di-desoxy-THC could be valuable approaches for identifying the behavioral consequence of THC potentiation of GlyRs in vivo. 
the time of tHc application. **P < 0.01, ***P < 0.001, using AnovA against α1 (n = 7). (c) the concentration response curves of tHc potentiation of i Gly in cells expressing different α subunits. *P < 0.05, **P < 0.01, using AnovA against α1 (n = 7-9). (d) Amino acid alignment of the tM3 region flanking Ser296 (α1) or equivalent residues in the α2 and α3 subunits. (e) the concentration response curves of tHc potentiation in cells expressing the wild-type (α1) and S296A mutant receptors. **P < 0.01, ***P < 0.001, AnovA against α1 (n = 7-9). (f) the concentration response curves of tHc potentiation in cells expressing the wild-type (α3) and S307A mutant receptors. *P < 0.05, **P < 0.01, AnovA against α3 (n = 5-6).
article NaTURE CHEMICaL BIoLoGy dOI: 10.1038/nCHeMBIO.552 whether or not GlyRs are involved in THC-induced analgesia in the TFR. Both THC and 5-desoxy-THC increased response latencies in the TFR in C57BL/6J mice (Fig. 6a) . The analgesic effects of THC and 5-desoxy-THC were completely abolished by administration of strychnine (14), a selective GlyR antagonist, and di-desoxy-THC but not by a selective CB1 receptor antagonist AM251. We next tested the effect of THC in the TFR in the α3 GlyR subunit knockout mice (α3 −/− ). The baseline of response latency was slightly increased in the TFR in α3 −/− mice. The analgesic effect of THC and 5-desoxy-THC was significantly reduced in heterozygous α3 +/− mice and completely absent in α3 −/− mice (Fig. 6b) . In contrast, both THCand 5-desoxy-THC-produced analgesia remained unchanged in CB1 −/− and CB2 −/− mice as compared to the wild-type littermates (Fig. 6c,d) . The magnitude of THC-induced and 5-desoxy-THCinduced analgesia increased with increasing drug concentrations up to 50 mg kg −1 (Supplementary Fig. 3a,b) . The analgesic Fig. 3a ). In contrast, the analgesic effect of THC at 30 mg-50 mg kg −1 , intraperitoneal (i.p.) injection, in the TFR was either absent or substantially reduced by 80% in the α3 −/− mice as compared with the wild-type mice (Supplementary Fig. 3a) . No significant difference was observed in the morphine-induced analgesic effect in the TFR between the α3 −/− mice and wild-type littermates (Fig. 6e) . Moreover, there was no significant difference in the THC-induced analgesic effect in the TFR between the α2 GlyR subunit knockout mice (α2 −/− ) and wild-type littermates (Fig. 6f) . While CB1 −/− mice showed no hypothermia after injection of the THC even at a high concentration (50 mg kg −1 ), the THC-induced hypothermia did not significantly differ between the α3 −/− and wild-type mice ( Supplementary  Fig. 3c ). We next examined the effects of 5-desoxy-THC and di-desoxy-THC on body temperature and locomotor activity in C57BL/6J mice. Both 5-desoxy-THC and di-desoxy-THC when administrated alone did not significantly affect locomotor activity and body temperature of the mice (Supplementary Fig. 3d,e) . Di-desoxy-THC at 20 mg kg −1 did not significantly alter THC (10 mg kg −1 )-induced hypothermia and hypolocomotor activity in the mice (Supplementary Fig. 3d,e) . However, both of these behavioral changes induced by THC were completely restored by administration of AM251 at 3 mg kg −1 respectively. While the TFR represents a spinal reflex, the hot plate test is considered to involve supraspinal processing 20 . We next measured the analgesic effect of THC and 5-desoxy-THC in the hot plate test. Consistent with previous studies 2 , THC increased response latency in the hot plate test (Supplementary Fig. 4a ). THC-induced anal gesia was prevented by administration of AM251 but not by strychnine and di-desoxy-THC (Supplementary Fig. 4a) . In contrast to the observation in the TFR, 5-desoxy-THC was ineffective in producing an analgesic effect in the hot plate test in the wild-type, α3 Fig. 4b-d) . The extent of increase in response latency by THC did not significantly differ between the α3 −/− mice and the wild-type littermates (Supplementary Fig. 4b ). Consistent with a previous report 2 , the THC-induced analgesic effect in the hot plate test was completely absent in the CB1 −/− mice but not in the CB2 −/− mice ( Supplementary Fig. 4c,d ). Several recent studies have shown that HU 210 (15), a synthetic CB1-receptor full agonist structurally similar to THC (Supplementary Fig. 5a ), can potentiate I Gly in HEK 293 cells expressing recombinant GlyRs 11, 12 . In view of this, we examined the analgesic effect of HU 210 in the TFR in CB −/− mice. Intraperitoneal administration of HU 210 20 min before the TFR produced analgesia in a dose-dependent manner from 3 mg kg −1 to 50 mg kg Fig. 5b ). In these mice, the extent of HU 210-induced analgesia in the TFR was slightly less than that of THC. The magnitude of the analgesic effect induced by HU 210 (10 mg kg −1 , i.p.) reached its maximum 20-30 min after drug injection and substantially reduced 50 min after drug injection (Supplementary Fig. 5c ). Di-desoxy-THC at 30 mg kg −1 significantly reduced the analgesic effect of HU 210 at 30 mg kg −1 in the TFR in CB −/− mice (Supplementary Fig. 5d ). Strychnine at 0.2 mg kg Fig. 5e,f) .
DISCUSSIoN
We have identified a physical site critical for the THC-induced potentiating effect on I Gly through functional mutagenesis of GlyRs. This conclusion is supported by the finding from NMR chemical shift measurements of the purified transmembrane domains of the α1 GlyR protein. THC is likely to interact with GlyRs through a hydrogen-bond interaction. This idea is consistent with previous studies of alcohol and anesthetic modulation of GABA A and glycine receptors. A cluster of polar amino acids in the TM2 and TM3 domains of these receptors have been found to play key roles in determining the receptor's sensitivity to various alcohols and anesthetics 21, 22 . Alternately, the antagonism of di-desoxy-THC against a THC-induced potentiating effect suggests that there are hydrophobic residues in the vicinity of transmembrane domains of GlyR that also contribute to THC modulation of GlyRs. The antagonism of di-desoxy-THC appeared to be selective for the THC-induced but not propofol-induced potentiating effect on I Gly . The simplest explanation is that a cavity exists among the transmembrane regions of GlyRs that may accommodate cannabinoids. There is a possibility that di-desoxy-THC may be a competitive inhibitor of the THCinduced effect if the concentrations of THC are high enough to overcome di-desoxy-THC. We had to set the cutoff concentration of both chemical compounds at 30 μM because of a solubility problem.
The results of the NMR chemical shift measurement favor a direct interaction between THC and residue Ser296 of GlyR-TM3. Chemical shift changes indicate changes in the electronic environment of the nuclei. The results from our titration experiments suggest that the environment near Ser296 is sensitively modulated by THC in a dose-dependent manner. Consistent with this, THC at low concentrations enhanced the function of the α1 and α3 GlyRs. Overall, these findings are not hard proof of a direct interaction but rather favor the simple explanation that a THC-GlyR interaction occurs in the vicinity of Ser296. THC is also likely to enhance GlyR channel activity through an allosteric mechanism, given the observation that the S296A-S307A mutations of the α1 and α3 subunits altered the efficacy but not the apparent affinity (EC 50 ) of THC potentiation of I Gly . The potency of a positive modulator may be more a function of ligand efficacy than affinity. This idea has been true with regard to many known allosteric modulators of GlyRs including alcohols and general anesthetics. It should be pointed out that several factors could prevent us from determining the precise EC 50 values of THC potentiation in electrophysiological experiments. These factors include agonist concentrations, receptor desensitization, drug solubility, receptor density and posttranslational modulation of receptor protein. Among these factors, the problem with cannabinoid solubility indeed limited our ability to obtain precise assessment of the EC 50 and E max of THC concentration response curve in the mutant receptors.
On the basis of the data presented in this study, we propose that the THC-induced analgesia in the TFR is likely mediated via a mechanism dependent on the α3 GlyRs. In contrast, the analgesia of THC in the hot plate test is predominantly mediated by CB1 receptors, suggesting that the TFR and the hot plate effect are mediated through distinct mechanisms. A spinal component is proposed to critically contribute to the mechanism underlying THC-induced analgesia in the TFR in mice 2, 23 . This correlates well with the observation that the α3 GlyRs are abundantly expressed in the dorsal horn of the spinal cord and is consistent with recent findings that spinal CB1 receptors may exert a pronociceptive action 6, 7 . However, several previous studies reported that pretreatment with a selective CB1 receptor antagonist, SR141716A (16), inhibited THC-induced analgesic effect in the TFR in mice 5, 24, 25 . There are several factors that could account for the discrepancy between our study and previous studies. For instance, SR141716A at pharmacological doses greater than 3 mg kg −1 has been shown to produce direct effects on locomotor activity and body temperature 5, 24 , AM251 used in our study did not significantly alter either behavior. In addition, different strains of mice were used in our (C57BL/6J) and previous studies (ICR). Mice with different genetic backgrounds may differ in their response to the THC-induced analgesic effect as well as other cannabimimetic side effects such as hypolocomotion, hypothermia and psychosis. These behavior alterations can further complicate the assessment of the THC analgesia 26 . Another contributing factor is the setting of the test parameters in the TFR test, such as tail-flick latency of control group. Different tail-flick latencies (1 s versus 4 s) used across laboratories could, therefore, contribute to some conflicting observations of THC-induced analgesia in the TFR test in CB1 −/− mice 2, 27 . The α3 GlyRs are thought to be an essential target for chronic inflammatory pain induced by PGE 2 and other nonpainful stimuli 28, 29 . It remains to be determined whether or not GlyRs could contribute to the therapeutic mechanisms of THC in the treatment of pathological pain. The role of the α1 GlyRs in cannabis-induced analgesia is unknown because we lack selective antagonists of GlyR subtypes and an ideal animal model 30 . Consistent with previous studies 10, 11 , detectable potentiation of I Gly by THC was observed at low concentrations (30-300 nM) in cultured neurons and in HEK 293 cells expressing the α1 and α3 subunits. This concentration range is in line with human plasma concentrations (400-500 nM) of THC at 10 min after smoking two cigarettes 31 . The maximal magnitude of THC potentiation required continuous incubation of the drug for 3-5 min. A similar scenario has been described in cannabinoid modulation of 5-HT 3 and nicotinic acetylcholine (nACh) receptors, close members of GlyRs in a ligand-gated ion channel superfamily 32, 33 . Because the E max concentrations of THC potentiation were significantly increased, the EC 50 values of THC potentiation of GlyRs were obtained in a lower micromolar range instead of the higher nanomolar range described previously 10, 11 . One can argue about the clinical relevance of THC potentiation of I Gly . It should be pointed out that the THC concentrations in brain and spinal tissues are found to be at least threefourfold higher than plasma THC concentrations, according to a study in mice 25 . Moreover, the THC concentration is credible for the measurement of the cannabis-induced psychoactive effects but less important for the cannabis-induced analgesia. Among 480 components of cannabis sativa, 65 are structurally related compounds, namely phytocannabinoids. Many of these cannabinoids with weak or no psychoactivity have therapeutic potentials. For instance, cannabidiol (17) , which is structurally similar to THC, has been used for the treatment of chronic pain in animals and human 9 . A recent study has shown that cannabidiol can enhance GlyR function in a manner similar to THC 34 . The concentrations of cannabidiol could be equal or close to the average concentrations of THC, which is estimated to be around 1-3% in overall cannabis preparations 31 . It is plausible to predict that the GlyRs could mediate some behavioral effects induced by other phytocannabinoids structurally similar to THC and cannabidiol. A previous observation that the analgesia of HU 210 in the TFR was absent in CB1 −/− mice 2 is contradictory with our finding in this study. This discrepancy could be because different time points were used to measure the analgesic effect of HU 210 in the TFR after drug injection. We observed that the extents of THC-and HU 210-induced analgesia reached its maximum within 20 min after drug injection and declined significantly 50 min after drug injections. The time course of THC-induced analgesia is consistent with cannabinoid pharmacokinetics measured in mice and humans 25, 31 . For instance, the peak concentration of THC occurred at 9 min in human plasma after smoking cannabis 31 .
The widespread medical use of cannabis has been the topic of many debates in the last few decades, extending beyond the medical and scientific communities. This topic has been so controversial because the plant can produce effects beyond the therapeutic. It is important to identify distinct mechanisms that underlie the therapeutic effects induced by cannabis via non-CB1 pathways. The mechanism of THC-GlyR interaction revealed in this study not only enhances our understanding of the role of GlyRs in cannabis-induced analgesia but also promotes a new avenue for developing analgesic agents. For instance, 5-desoxy-THC appears to be one of the enticing candidates that produce an analgesic effect without causing a psychoactive effect. Except for antinociceptive action, cannabinoids and GlyRs play similar roles in the processes of neuromotor activity, seizure, anxiety, drugs of abuse and muscle relaxation 1, 35 . The α1 and α3 GlyRs are abundantly expressed in many brain regions 13, 36 . Our findings here also open up an opportunity to develop new genetically modified mice, which together with 5-desoxy-THC and di-desoxy-THC could be valuable for exploring the role of GlyRs in some of the nonpsychotropic cannabinoid-induced behaviors in future studies.
Collectively, these findings have revealed the molecular basis of THC potentiation of GlyRs and the role of GlyRs in some of cannabis-induced behaviors. The new mechanism underlying THC potentiation and certain types of cannabinoid-induced analgesia can potentially lead to a strategy for the development of a new class of analgesic agents.
METHoDS
Animals.
All behavioral experiments were conducted in male C57BL/6J mice unless otherwise indicated. The α3 Glra +/− mice were bred with each other to generate experimental animals: wild-type, α3 Glra +/− and α3 Glra −/− littermates. The CB1 −/− , CB2
−/− and α2 Glra −/− mice were generated as previously described 2, 37, 38 . The homozygous mutants of the mice listed above were backcrossed into the C57BL/6J background for at least six generations and genotyped using primers given in the Supplementary Methods.
